Nanoscale Res Lett 2012, 7:88. 10.1186/1556-276X-7-88CrossRef 19. Born M, Wolf E: Principles of Optics. 6 corrth edition. Oxford: Pergamon Press; 1986:329. 20. Bosch S, Ferré-Borrull J, Sancho-Parramon J: A general-purpose software for optical characterization of thin films: specific features for microelectronic applications. Solid State Electron 2001, 45:703–709. 10.1016/S0038-1101(01)00092-2CrossRef 21. Masuda H, Fukuda K: Ordered metal nanohole arrays made by a two-step replication of honeycomb structures of anodic alumina. Science 1995, 268:14661468.CrossRef 22. Santos A, Selleckchem Foretinib Balderrama VS, Alba M, Formentín P, Ferré-Borrull J, Pallarès J, Marsal LF: Nanoporous anodic alumina

barcodes: toward smart optical biosensors. Adv Mater 2012, 24:1050–1054. 10.1002/adma.201104490CrossRef 23. Nielsch K, Choi J, Schwirn K, Wehrspohn RB, Gösele U: Self-ordering regimes of porous alumina: the

10% porosity rule. selleck kinase inhibitor Nano Lett 2002, 2:677–680. 10.1021/nl025537kCrossRef 24. Abràmoff MD, Magalhaes PJ, Ram SJ: Image processing with ImageJ. Biophoton Int 2004, 11:36–42. 25. Palik ED: Handbook of Optical Constants of Solids. San Diego, CA: Academic; 1998. 26. Ahmad N, Stokes J, Fox NA, Teng M, Cryan MJ: Ultra-thin metal films for enhanced solar absorption. Nano Energy 2012, 1:777–782. arXiv: 1202.6603V2 [physics.optics] 10.1016/j.nanoen.2012.08.004CrossRef 27. Macías G, Hernández-Eguía LP, Ferré-Borrull J, Pallares J, Marsal LF: Gold-coated ordered nanoporous anodic alumina bilayers for future label-free interferometric biosensors. Veliparib manufacturer ACS Appl Mater Interf 2013, 5:8093–8098. 10.1021/am4020814CrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions LPHE designed the geometry of the NAA

samples, carried out the reflectance measurements, performed the simulations, and drafted the manuscript. GM fabricated the NAA samples and helped in the manuscript elaboration. JFB made substantial contributions Morin Hydrate to the analysis and interpretation of theoretical simulations, and JP and LFM coordinated all the experiments and gave final approval of the version to be submitted. All authors help to draft the article and approved the final manuscript.”
“Background Nanoporous anodic alumina (NAA) is a material of great interest in nanotechnology because of its cost-effective and easily up-scalable production techniques [1–3] and also because of its vast field of applications [4–8]. This material consists of an array of cylindrical pores in an aluminum oxide matrix obtained by electrochemical anodization of aluminum. In the appropriate fabrication conditions, the pores self-arrange in a triangular lattice with domains containing several hundreds of pores [9]. This pore arrangement is usually obtained with three kinds of acid electrolytes (oxalic, phosphoric, or sulfuric) and in two different regimes, known as hard and mild anodization [10].

For instance, human caspase-3 gene therapy was used in addition to etoposide treatment in an AH130 liver tumour model and was found to induce extensive apoptosis and reduce tumour volume [102] while gene transfer of constitutively active caspse-3 into HuH7 human hepatoma

cells selectively induced apoptosis in these cells [103]. Also, a recombinant adenovirus carrying immunocaspase 3 has been shown to exert anti-cancer effects in hepatocellular carcinoma in vitro and in vivo [104]. 4.5 Molecules targeting apoptosis in clinical trials Recently, many new molecules that target apoptosis enter various stages of clinical trials. A search at http://​www.​clinicaltrials.​gov (a registry and results Y-27632 ic50 database of federally and privately supported clinical trials conducted in the United States and around the world) returns many results. These molecules target Epigenetics inhibitor various proteins involved in apoptosis. Many are antagonists of IAPs and molecules that target the Bcl-2 family of mTOR phosphorylation proteins. Table

3 summarises ongoing or recently completed clinical trials involving molecules that target apoptosis. Table 3 Ongoing or recently completed clinical trials involving molecules that target apoptosis Molecule name Sponsor Target Condition Clinical stage ABT-263 (in combination with erlotinib or irinotecan) Abbott Bcl-2 family of proteins Solid tumours Phase I ABT-263 (in combination with docetaxel) Abbott Bcl-2 family of proteins Solid tumours Phase I ABT-263 (in combination with paclitaxel) Abbott Bcl-2 family of proteins Chronic lymphocytic leukaemia Phase I ABT-263 Genentech Bcl-2 family of proteins Chronic lymphocytic leukaemia Phase II AT-101 (Gossypol) Roswell Park Cancer Institute Bcl-2 family of proteins Lymphocytic leukaemia, chronic B-cell leukaemia Phase I Phase II AT-406 Ascenta Carbohydrate Therapeutics IAPs Solid tumours, lymphoma Phase I AT-406 Ascenta Therapeutics IAPs Acute myelogenous leukaemia Phase I ENZ-3042 Therapeutic Advances in Childhood Leukaemia Consortium IAPs Acute, childhood and T cell lymphoblastic leukaemia Phase I GX15-070MS (Obotoclax)

Children’s Oncology Group Bcl-2 family of proteins Leukaemia, lymphoma unspecified childhood solid tumour Phase I GX15-070MS (Obotoclax) Arthur G. James Cancer Hospital & Richard J. Solove Research Institute Bcl-2 family of proteins Lymphoma Phase I Phase II HGS-1029 Human Genome Sciences IAPs Advanced solid tumours Phase I HGS-1029 Human Genome Sciences IAPs Advanced solid tumours Phase I LCL-161 Novartis Pharmaceuticals IAPs Solid tumours Phase I RO5458640 Hoffmann-La Roche TNF-like weak inducer of apoptosis (TWEAK) ligand Advanced solid tumours Phase I 5. Conclusions The abundance of literature suggests that defects along apoptotic pathways play a crucial role in carcinogenesis and that many new treatment strategies targeting apoptosis are feasible and may be used in the treatment of various types of cancer.